A compound of Formula 2: for use in the treatment of focal segmental glomerulosclerosis; wherein R 1 and R 2, which may be the same or different, are selected from the group consisting of a C 1 to C 10 alkyl, C 3 to C 10 cycloalkyl, C 3 to C 10 cycloalkylmethyl, C 3 to C 10 alkene, C 3 to C 10 alkyne and a chain containing a heterocyclic or fused ring, any of which may be optionally substituted; X 1 and X 2 are the same or different and are selected from the group consisting of a bond, O, N and S; T is a single or double bond; R 3 is selected from the group consisting of H, C 3 to C 10 alkene, C 3 to C 10 alkyne and a chain containing a heterocyclic or fused ring, any of which may be optionally substituted; R 4 is selected from the group consisting of H, OH, OR 6, NHR 6 and NR 6 R 7; R 5 is selected from the group consisting of H, NHR 6, NR 6 R 7, ORs, halogen, C 3 to C 10 alkene, C 3 to C 10 alkyne and a chain consisting of a heterocyclic or fused ring, any of which may be optionally substituted; R 6 and R 7, which may be the same or different, are selected from the group consisting of H, C 1 to C 10 alkyl, C 3 to C 10 cycloalkyl, C 3 to C 10 cycloalkylmethyl, C 3 to C 10 alkene, C 3 to C 10 alkyne, aryl, C 5 to C 20 alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted; R 8 is selected from the group consisting of H, C 1 to C 10 alkyl, C 3 to C 10 cycloalkyl, C 3 to C 10 cycloalkylmethyl, C 3 to C 10 alkene, C 3 to C 10 alkyne, aryl, C 5 to C 20 alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted; and n is an integer between 0 and 4; or pharmaceutically acceptable salts thereof; with the proviso that when X 1 and X 2 are both O or a bond, and one of R 1 or R 2 is a C 1 to C 4 alkyl, the other of R 1 or R 2 is a C 4 to C 10 alkyl, C 3 to C 10 cycloalkyl, C 3 to C 10 cycloalkylmethyl, C 3 to C 10 alkyne, or a chain containing a heterocyclic or fused ring; and with the proviso that the compound is not Tranilast. wherein R 1 and R 2, which may be the same or different, are selected from the group consisting of a C 1 to C 10 alkyl, C 3 to C 10 cycloalkyl, C 3 to C 10 cycloalkylmethyl, C 3 to C 10 alkene, C 3 to C 10 alkyne and a chain containing a heterocyclic or fused ring, any of which may be optionally substituted; X 1 and X 2 are the same or different and are selected from the group consisting of a bond, O, N and S; T is a single or double bond; R 3 is selected from the group consisting of H, C 3 to C 10 alkene, C 3 to C 10 alkyne and a chain containing a heterocyclic or fused ring, any of which may be optionally substituted; R 4 is selected from the group consisting of H, OH, OR 6, NHR 6 and NR 6 R 7; R 5 is selected from the group consisting of H, NHR 6, NR 6 R 7, ORs, halogen, C 3 to C 10 alkene, C 3 to C 10 alkyne and a chain consisting of a heterocyclic or fused ring, any of which may be optionally substituted; R 6 and R 7, which may be the same or different, are selected from the group consisting of H, C 1 to C 10 alkyl, C 3 to C 10 cycloalkyl, C 3 to C 10 cycloalkylmethyl, C 3 to C 10 alkene, C 3 to C 10 alkyne, aryl, C 5 to C 20 alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted; R 8 is selected from the group consisting of H, C 1 to C 10 alkyl, C 3 to C 10 cycloalkyl, C 3 to C 10 cycloalkylmethyl, C 3 to C 10 alkene, C 3 to C 10 alkyne, aryl, C 5 to C 20 alkaryl, and a hydrocarbon chain containing a heterocyclic or fused ring, any of which may be optionally substituted; and n is an integer between 0 and 4; or pharmaceutically acceptable salts thereof; with the proviso that when X 1 and X 2 are both O or a bond, and one of R 1 or R 2 is a C 1 to C 4 alkyl, the other of R 1 or R 2 is a C 4 to C 10 alkyl, C 3 to C 10 cycloalkyl, C 3 to C 10 cycloalkylmethyl, C 3 to C 10 alkyne, or a chain containing a heterocyclic or fused ring; and with the proviso that the compound is not Tranilast.